IBRUTINIB
ibrutinib 280 mg tablet, 30
IBRUTINIB (14579H)
14579H
Manner of administration:Oral
Restriction
Indication: Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
Treatment phase: Grandfather treatment - Transitioning from non-PBS to PBS-subsidised supply of first-line
therapy
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 30 | # of repeats: 5 | DPMQ: $5,357.30 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
|
|
|||||